^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
PTEN overexpression
i
Other names: PTEN, Phosphatase and tensin homolog, Mutated In Multiple Advanced Cancers 1, Phosphatase And Tensin Homolog, Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN, MMAC1, TEP1, MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10, Mitochondrial Phosphatase And Tensin Protein Alpha, Phosphatase And Tensin-Like Protein, Protein Tyrosine Phosphatase, Mitochondrial PTENalpha, PTENbeta, PTEN1, CWS1, GLM2, MHAM
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
11d
Transcriptional factor KLF9 overcomes 5-fluorouracil resistance in breast cancer via PTEN-dependent regulation of aerobic glycolysis. (PubMed, J Chemother)
In conclusion, the TF KLF9 inhibits the aerobic glycolysis level of breast cancer cells by up-regulating PTEN expression, thereby reducing their resistance to 5-FU. The discovery of this mechanism provides a new theoretical basis for the treatment of breast cancer.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression • PTEN overexpression
|
5-fluorouracil
30d
PTEN Deficiency Induced by Extracellular Vesicle miRNAs from Clonorchis sinensis Potentiates Cholangiocarcinoma Development by Inhibiting Ferroptosis. (PubMed, Int J Mol Sci)
Erastin was used to construct ferroptosis induction models...Mechanistically, csi-miR-96-5p and PTEN knockout significantly inhibited ferroptosis through a decrease in ferrous ion (Fe2+) and malondialdehyde (MDA), and an increase in glutathione reductase (GSH), Solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). In conclusion, loss of PTEN promoted the progression of cholangiocarcinoma via the ferroptosis pathway and csi-miR-96-5p delivered by CS-EVs may mediate this process.
Journal
|
PTEN (Phosphatase and tensin homolog) • GPX4 (Glutathione Peroxidase 4) • MIR96 (MicroRNA 96) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
PTEN expression • PTEN overexpression
|
erastin
6ms
A high dose KRP203 induces cytoplasmic vacuoles associated with altered phosphoinositide segregation and endosome expansion. (PubMed, Biochem Biophys Res Commun)
These results suggest a model that noncanonical spatial reorganization of phosphoinositides by KRP203 alters the endosomal maturation process, leading to vacuolization. Taken together, this study reveals a previously unrecognized bioactivity of KRP203 as a vacuole-inducing agent and its unique mechanism of phosphoinositide modulation, providing a new insight of phosphoinositide regulation into vacuolization-associated diseases and their molecular pathologies.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression • PTEN overexpression
|
mocravimod (KRP-203)
7ms
DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma. (PubMed, Dig Dis Sci)
Our findings firstly confirmed that circDDX17 suppressed sorafenib resistance and HCC progression by regulating miR-21-5p/PTEN/PI3K/AKT pathway, which may provide novel biomarkers for the diagnosis, treatment and prognosis of HCC.
Journal
|
MIR21 (MicroRNA 21) • DDX1 (DEAD-Box Helicase 1) • DDX17 (DEAD-Box Helicase 17)
|
PTEN expression • PTEN overexpression
|
sorafenib
8ms
PTEN decreases NR2F1 expression to inhibit ciliogenesis during EGFRL858R-induced lung cancer progression. (PubMed, Cell Death Dis)
PTEN acts as a double-edged sword that differentially regulates EGFRL858R-induced lung cancer progression in different genomic backgrounds. Understanding the PTEN in lung cancer with different genetic backgrounds will be beneficial for therapy in the future.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
|
KRAS mutation • EGFR mutation • EGFR L858R • PTEN expression • PTEN overexpression • PTEN negative
9ms
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation. (PubMed, J Exp Clin Cancer Res)
Our findings, for the first time, demonstrate that overexpressed SNHG1 competes with USP8 for binding to HUR. This competition attenuates USP8 mRNA stability and protein expression, leading to PTEN protein degradation, consequently, this process drives urothelial cell malignant transformation and fosters BMIBC growth and primary BMIBC formation.
Journal
|
PTEN (Phosphatase and tensin homolog) • SNHG1 (Small Nucleolar RNA Host Gene 1)
|
PTEN expression • PTEN overexpression
9ms
OVEREXPRESSION OF PTEN GENE INCREASES INS2 GENE MRNA EXPRESSION, NOT INS1 GENE MRNA EXPRESSION, IN INSULINOMA CELL LINE RIN-5F. (PubMed, Acta Endocrinol (Buchar))
The present study suggested that overexpression of PTEN might induce the increasing Ins 2 gene expression, one of the phosphorylated genes against the IRS-2 through the insulin/IGF-1 receptor. Our knowledge of the molecular pathways of PTEN relating the synthesis of insulin has been increased by the present study.
Preclinical • Journal
|
PTEN (Phosphatase and tensin homolog) • IGF1 (Insulin-like growth factor 1) • IRS2 (Insulin receptor substrate 2)
|
PTEN expression • PTEN overexpression
11ms
csi-miR-96-5p delivered by Clonorchis sinensis extracellular vesicles promotes intrahepatic cholangiocarcinoma proliferation and migration via the ferroptosis-related PTEN/SLC7A11/GPX4 axis. (PubMed, Parasit Vectors)
csi-miR-96-5p delivered by CsEVs reduced ferroptosis by regulating the expression of the PTEN/SLC7A11/GPX4 axis, thereby promoting ICC proliferation and migration. For the first time to our knowledge, we found that CS miRNAs could promote tumor development through ferroptosis.
Journal
|
PTEN (Phosphatase and tensin homolog) • GPX4 (Glutathione Peroxidase 4) • MIR96 (MicroRNA 96) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
PTEN expression • PTEN-L • PTEN overexpression
|
erastin
11ms
Recapitulation of anti-aging phenotypes by global overexpression of PTEN in mice. (PubMed, Geroscience)
These changes in fat, macrophages, liver, muscle, hippocampus, and plasma may be considered "aging rate indicators" in that they seem to be consistently changed across many of the long-lived mouse models and may help to extend lifespan by delaying many forms of late-life illness. Our new findings show that PTENOE mice can be added to the group of long-lived mice that share this multi-tissue suite of biochemical characteristics.
Preclinical • Journal
|
PTEN (Phosphatase and tensin homolog) • IGF1 (Insulin-like growth factor 1) • ARG1 (Arginase 1) • BDNF (Brain Derived Neurotrophic Factor)
|
PTEN mutation • PTEN expression • PTEN overexpression • PTEN negative
11ms
Overexpression of HMGB1 in hepatocytes accelerates PTEN inactivation-induced liver cancer. (PubMed, Hepatol Commun)
Overexpression of HMGB1 in hepatocytes accelerates liver tumorigenesis in Pten∆Hep mice, enhancing cell proliferation and F4/80+ cells to drive MASH-induced liver cancer.
Journal
|
PTEN (Phosphatase and tensin homolog) • HMGB1 (High Mobility Group Box 1) • SOX9 (SRY-Box Transcription Factor 9)
|
PTEN overexpression • HMGB1 overexpression
11ms
PTEN expression can be used as a switch between senescence and apoptosis in breast cancer cells according to a logical model of the G2/M checkpoint. (PubMed, Biosystems)
Furthermore, we demonstrate that miR-21 can be used as a target against proliferation control because its knockout is equivalent to PTEN overexpression. We think the findings can be used to motivate new strategies for MCF-7 strain proliferation control.
Journal
|
ER (Estrogen receptor) • PTEN (Phosphatase and tensin homolog) • mTOR (Mechanistic target of rapamycin kinase) • MIR21 (MicroRNA 21)
|
ER positive • PTEN expression • PTEN overexpression • miR-21 overexpression
12ms
Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer. (PubMed, Virchows Arch)
In conclusion, our results indicate that UF and MF PCa have relevant and consistent molecular differences. The analysis of an immunohistochemical panel, composed by PTEN, SPOP, SLC45A3, ETV1 and ERG, could be useful to predict outcome in MF cases.
Journal
|
PTEN (Phosphatase and tensin homolog) • SPOP (Speckle Type BTB/POZ Protein) • ETV1 (ETS Variant Transcription Factor 1) • SLC45A3 (Solute Carrier Family 45 Member 3)
|
PTEN expression • PTEN overexpression • ERG overexpression • ETV1 overexpression
1year
Image biomarker discovery from DCE-MRI for identifying responders of MK-2206 on early-stage breast cancer patients: A secondary radio-genomics analysis of I-SPY2 trial (ESMO Asia 2023)
GLCM_SS+ also showed distinct gene profiles enriched in immune signaling. Further experiments are planned to verify the radiogenomics association with GLCM_SS+ sensitivity to MK-2206.
Clinical • Genomic analysis
|
HER-2 (Human epidermal growth factor receptor 2) • PTEN (Phosphatase and tensin homolog)
|
HER-2 negative • PTEN expression • PTEN overexpression
|
MammaPrint
|
MK-2206
1year
Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers. (PubMed, Front Endocrinol (Lausanne))
In-vitro functional assays have further demonstrated that a combination of Idelalisib and SRPIN340 achieved a synergistic drug effect (with drastically reduced cell viabilities/growths of tumor spheroids) in inhibiting the advanced tumor cells. In summary, our study has suggested a promising potential of utilizing PI3Kδ-S (an oncogenic isoform conferring drug resistance and exempt from PTEN regulation) as a prognostic biomarker and drug target in advanced endocrine cancers.
Journal
|
PTEN (Phosphatase and tensin homolog) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • SRPK1 (SRSF Protein Kinase 1)
|
PTEN expression • PIK3CD expression • PTEN overexpression • PTEN negative
|
Zydelig (idelalisib)
1year
The effects of the tumor suppressor gene PTEN on the proliferation and apoptosis of breast cancer cells via AKT phosphorylation. (PubMed, Transl Cancer Res)
Overexpression of the PTEN gene can promote AKT phosphorylation, increase the apoptotic index of breast cancer cells, and reduce the proliferative activity of breast cancer cells. This provided a new direction for the next treatment of breast cancer, but further clinical research is needed.
Journal
|
PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • mTOR (Mechanistic target of rapamycin kinase)
|
PTEN expression • PTEN overexpression
1year
HTRA3 transcriptionally inhibited by FOXP1 suppresses tumorigenesis of osteosarcoma via the PTEN/PI3K/AKT pathway. (PubMed, Biochim Biophys Acta Mol Cell Res)
Detailed investigations showed that forkhead box protein 1 (FOXP1), an oncogene in OS progression, downregulated HTRA3 expression and inhibited the transcriptional activity of HTRA3, suggesting that HTRA3 was regulated negatively by FOXP1. In conclusion, our study demonstrates that HTRA3 is a repressor involved in OS development via the PTEN/PI3K/AKT pathway under the modulation of transcription factor FOXP1, and it may provide a therapeutic direction for OS patients.
Journal
|
FOXP1 (Forkhead Box P1) • XIAP (X-Linked Inhibitor Of Apoptosis) • HTRA3 (HtrA Serine Peptidase 3)
|
PTEN expression • PTEN overexpression
over1year
Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway. (PubMed, Heliyon)
Preoperative FIB could be related with the prognosis of PLC patients, the risk of death in PLC patients gradually increases along with the up-regulation of FIB. FIB may promote hepatoma metastasis by inducing EMT via the activation of PTEN/AKT/mTOR pathway.
Journal
|
PTEN overexpression
over1year
USP22 knockdown protects against cerebral ischemia/reperfusion injury via destabilizing PTEN protein and activating the mTOR/TFEB pathway. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
USP22 expression levels were negatively correlated with mTOR expression levels, and USP22-shRNA-mediated expression of p62, p-mTOR, TFEB, and LAMP1 was reversed by rapamycin, an inhibitor of mTOR. In vivo, USP22 silencing significantly alleviated infarct volume, neurobehavioral impairments, cell apoptosis, oxidative stress, and autophagy in MCAO/R mice. USP22 knockdown exerts neuroprotective effects in cerebral ischemia/reperfusion injury by downregulating PTEN and activating the mTOR/TFEB pathway.
Journal
|
PTEN (Phosphatase and tensin homolog) • LAMP1 (Lysosomal Associated Membrane Protein 1) • TFEB (Transcription Factor EB 2) • USP22 (Ubiquitin Specific Peptidase 22)
|
PTEN expression • PTEN overexpression
|
sirolimus
over1year
The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients. (PubMed, BMC Cancer)
PIK3CA mutations are associated with resistance to NAC but do not affect the response to NAE. Low PTEN expression does not affect response to either NAC or NAE but correlates with shorter RFS in patients who received NAC. These biomarkers will be further evaluated for clinical use to treat postmenopausal luminal breast cancer patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
|
ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • PTEN expression • EGFR positive • PIK3CA expression • PIK3CA wild-type • PTEN-L • PGR expression • PTEN overexpression
over1year
CircRNA circ_POLA2 overexpression suppresses cell apoptosis by downregulating PTEN in glioblastoma. (PubMed, Anticancer Drugs)
Moreover, PTEN reduced the inhibitory effects of circ_POLA2 on GBM cell apoptosis. Circ_POLA2 is overexpressed in MCL and might promote GBM cell apoptosis through downregulating PTEN.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression • PTEN overexpression
almost2years
β-catenin and PTEN as Predictive Biomarkers of Response to Progestin Therapy for Patients with Endometrioid Precancers (USCAP 2023)
Significantly more aberrancy of PTEN and β-catenin in non-responders indicates that these two may be associated with poor outcome of progestin therapy, while Pax2 is not. Among the 3 PPB markers, newly emerged β-catenin aberrancy in any F/U biopsies may be indicative of progestin resistance. Studies with a larger sample size are needed to confirm the findings.
Clinical
|
PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PAX2 (Paired Box 2)
|
PTEN overexpression
almost2years
PRLR and CACNA2D1 Impact the Prognosis of Breast Cancer by Regulating Tumor Immunity. (PubMed, J Pers Med)
Mechanistically, PRLR might affect the prognosis of BC by inhibiting the expression of immune checkpoints, while CACNA2D1 might improve the prognosis of BC by increasing the immune cells infiltrating into BC and up-regulating the expression of immune checkpoints. The abnormal expression of PRLR and CACNA2D1 in BC is closely related to the prognosis of BC, and they may serve as targets for the treatment of BC.
Journal
|
PTEN (Phosphatase and tensin homolog) • PRLR (Prolactin Receptor 2)
|
PTEN overexpression
2years
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN overexpression
2years
PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells. (PubMed, Front Surg)
Decreased PTEN expression in SBC, at the protein and gene levels, is associated with reduced PFS. PTEN knockdown in chordoma cells led to enhanced proliferation and invasiveness.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression • PTEN-L • PTEN overexpression
2years
PTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer. (PubMed, Onco Targets Ther)
Further, TCGA data validated that PTEN was indeed correlated with histological grade and invasion depth and positively related to PD-L1 expression (R = 0.29, adjusted P < 0.001). The above results suggested that PTEN expression was a useful marker in gastric carcinogenesis and progression and in the selection of immunotherapy-based treatments for GC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PTEN (Phosphatase and tensin homolog)
|
PD-L1 expression • PTEN expression • PTEN overexpression
2years
Comprehensive analysis to identify a novel PTEN-associated ceRNA regulatory network as a prognostic biomarker for lung adenocarcinoma. (PubMed, Front Oncol)
Quantitative PCR (qPCR) and immunohistochemical (IHC) analysis were used to detect predicted target genes. Therefore, we revealed that the PTEN-related LINC00460/miR-150-3p axis based on ceRNA mechanism plays an important role in the development of LUAD and provides a new direction and theoretical basis for its targeted therapy.
Journal
|
PTEN (Phosphatase and tensin homolog) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • LINC00460 (Long Intergenic Non-Protein Coding RNA 460) • MIR150 (MicroRNA 150)
|
PTEN deletion • PTEN expression • PTEN-L • PTEN overexpression
2years
Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss. (PubMed, JCO Precis Oncol)
PTEN low expression/gene loss is an independent significant prognostic factor and a promising component to strengthen the clinical prognostic tools in patients with localized GIST.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression • PTEN-L • PTEN overexpression
2years
Construction and validation of a glioblastoma prognostic model based on immune-related genes. (PubMed, Front Neurol)
Finally, the expression levels of TNC and SSTR2 were confirmed to be significantly associated with patient prognosis by protein mass spectrometry and WB. Herein, a robust predictive model based on IRGs was developed to predict the OS of GBM patients and to aid future clinical research.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase) • SSTR2 (Somatostatin Receptor 2)
|
IDH1 mutation • PTEN mutation • MGMT promoter methylation • PTEN overexpression
over2years
Evaluation of doxorubicin in three-dimensional culture of breast cancer cells and the response in PI3K/AKT/PTEN signaling pathways: a pilot study. (PubMed, Women Health)
D1 vs. D9 exhibited reduced VEGF-A, HIF-1α, and PIK3CA expression and upregulation of PTEN expression. DOX effects at the molecular mechanisms can be involved the modulation of genes related to angiogenesis cell proliferation and tumor growth in BC tissue spheroids.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
PTEN expression • PIK3CA expression • HIF1A expression • PTEN overexpression • VEGFA expression
|
doxorubicin hydrochloride
over2years
Genetic alteration profiling of Chinese lung adenocarcinoma: A targeted and immunotherapy biomarker analysis. (ASCO 2022)
These findings may be helpful for identifying therapeutic targets strategies in lung adenocarcinoma patients that were previously unavailable to clinicians in China.
Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • PD-1 (Programmed cell death 1) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
PD-L1 expression • TP53 mutation • KRAS mutation • BRCA1 mutation • EGFR mutation • TMB-H • MSI-H/dMMR • PIK3CA mutation • PTEN mutation • EGFR mutation + PTEN mutation • PTEN overexpression
|
PD-L1 IHC 22C3 pharmDx
over2years
Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis. (PubMed, Brain Sci)
PTEN gene mutations prevail in GBMs and are strongly related to poor prognosis and least survival. The infiltrating immune lymphocytes T and M2 macrophages populate the glioma microenvironment and control the mechanisms of tumor progression, immune escape, and sensitivity to standard chemotherapy. Broader studies are required to confirm these findings and turn them into new therapeutic perspectives.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN mutation • PTEN expression • PTEN overexpression
|
temozolomide
over2years
PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy. (PubMed, Breast Cancer Res Treat)
Low PTEN expression and high methylation of its promoter (sequence - 819 to - 787 bp) in tissue predict poor DFS and OS in hormone receptor-positive early BC patients who received adjuvant TAM.
Clinical • Journal
|
PTEN (Phosphatase and tensin homolog)
|
HR positive • PTEN expression • PTEN-L • PTEN overexpression
|
tamoxifen
almost3years
PD-L1 (22C3) Expression and Molecular Alterations in Ovarian Carcinomas (USCAP 2022)
"Our study did not reveal a difference in TMB and LOH between PD-L1 positive and PD-L1 negative ovarian carcinomas. Correlation between PD-L1 expression and PTEN mutation is demonstrated. The significance of this correlation likely warrants further investigation."
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • MLH1 (MutL homolog 1) • CHEK2 (Checkpoint kinase 2) • PIM1 (Pim-1 Proto-Oncogene) • CCND3 (Cyclin D3) • MUTYH (MutY homolog)
|
PD-L1 expression • PD-L1 overexpression • HRD • PTEN mutation • PD-L1 negative • CHEK2 mutation • PTEN expression • PTEN overexpression
|
PD-L1 IHC 22C3 pharmDx
almost3years
Genomic Classification of Clinically Advanced Prostate Cancer (CAPC) Based on Methylthioadenosine Phosphorylase (MTAP) Genomic Loss (USCAP 2022)
A small number of cases of CAPC have MTAP loss (1.3%). MTAP loss is associated with a higher mean TMB, and has a significantly different GA profile, indicating a potential benefit for directed therapy of CAPC based on MTAP status. Of particular interest, CAPC with MTAP loss has lower frequencies of GA in AR, CDK12 and RB1, and higher frequencies of GA in CDKN2A, CDKN2B, TP53.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • PARP Biomarker • BRCA Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MTAP (Methylthioadenosine Phosphorylase) • CDK12 (Cyclin dependent kinase 12) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ERG (ETS Transcription Factor ERG) • SPOP (Speckle Type BTB/POZ Protein) • RAD21 (RAD21 Cohesin Complex Component)
|
PD-L1 expression • CDKN2A deletion • SPOP mutation • TMPRSS2-ERG fusion • CDKN2B deletion • PTEN overexpression
|
PD-L1 IHC 22C3 pharmDx
3years
From metastatic melanoma to papillary thyroid cancer - would you have thought of Cowden's syndrome? (ADO 2021)
Since the patient BRAF-V600 is mutated, adjuvant therapy with the BRAF / MEK inhibitors dabrafenib 150 mg 1-0-1 and trametinib 2 mg 1-0-0 was initiated in November 2019, which in November 2020 after 1 year of adjuvant ended...therapy with nivolumab 480 mg iv every 4 weeks was initiated...therapy with nivolumab 480 mg iv every 4 weeks was initiated... If multiple neoplasms occur in young patients, Cowden's syndrome (germ cell mutation in the tumor suppressor gene PTEN) should be considered. The diagnosis is made on the basis of a combination of major (e.g. medullary thyroid cancer, endometrial cancer) and minor criteria (e.g.
PD(L)-1 Biomarker
|
PTEN (Phosphatase and tensin homolog)
|
BRAF mutation • BRAF V600 • PTEN mutation • PTEN overexpression
|
Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib)
3years
PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer. (PubMed, Cancers (Basel))
Automatic PTEN scoring was strongly predictive of the PTEN status assessed by human experts (area under the curve 0.987 (95% CI 0.968 to 0.994)). This suggests that PTEN status can be accurately assessed using ML, and that the combined marker of automatically assessed PTEN and DNA ploidy status may provide an objective supplement to the existing risk stratification factors in prostate cancer.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN-L • PTEN overexpression
over3years
ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. (PubMed, Cancers (Basel))
This clinical impact was observed in the less aggressive CLL subtype with mutated IGHV in which high ENDOG and low PTEN levels were associated with worse outcome. In summary, our results show that reducing ENDOG expression hinders growth of some tumors characterized by low PTEN activity and high p-AKT expression and that ENDOG has prognostic value for some cancer types.
Journal
|
PTEN (Phosphatase and tensin homolog) • IGH (Immunoglobulin Heavy Locus)
|
PTEN expression • PTEN-L • PTEN overexpression
over3years
Alterations of PTEN and SMAD4 methylation in diagnosis of breast cancer: implications of methyl II PCR assay. (PubMed, J Genet Eng Biotechnol)
Methylation status of PTEN and SMAD4 is a promising blood marker for early detection of breast cancer. Future studies are needed for their role as prognostic markers.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • SMAD4 (SMAD family member 4)
|
HER-2 positive • HER-2 negative • ER negative • PTEN overexpression
over3years
Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally-Metastatic Prostate Cancer. (PubMed, J Urol)
Through genomic profiling of PCa across various metastatic sites, we identified an extremely low frequency of AR alterations in pmPCa, high prevalence of DDR pathway deficiency in hmPCa and high PTEN alteration rates in vmPCa. We discovered the genomic diversity among bmPCa, hmPCa and pmPCa. Our findings shed new light on the heterogenous prognosis in visceral metastases and hint potential therapeutic targets in both hmPCa and pmPCa.
Journal • Next-generation sequencing
|
PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor)
|
PTEN overexpression
almost4years
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. (PubMed, Cancer)
The addition of copanlisib to gemcitabine and cisplatin does not improve PFS at 6 months. However, future studies using PTEN as a potential biomarker should be considered.
P2 data • Journal • Combination therapy
|
PTEN (Phosphatase and tensin homolog)
|
PTEN expression • PTEN-L • PTEN overexpression
|
cisplatin • gemcitabine • Aliqopa (copanlisib)
almost4years
Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation. (PubMed, Oncogene)
Taken together, we show that Smurf1 promotes tumor progression via PTEN, and combined treatment of Smurf1 knockdown with mammalian target of rapamycin (mTOR) inhibition reduces tumor progression. These results identify a unique role of Smurf1 in mTOR inhibitor resistance and provide a strong rationale for combined therapy targeting GBM.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN mutation • PTEN overexpression
Share via
